BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Finkelstein SE, Fishman M. Clinical opportunities in combining immunotherapy with radiation therapy. Front Oncol 2012;2:169. [PMID: 23233905 DOI: 10.3389/fonc.2012.00169] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Liu Z, Luo Z, Tan Y, Pang J, Chen J. Mathematical models and dynamic behaviors of cancer treatment by continuous and pulsed radiotherapy. J Appl Math Comput 2022. [DOI: 10.1007/s12190-022-01813-z] [Reference Citation Analysis]
2 Zhang Y, Xu Z, Chen H, Sun X, Zhang Z. Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer. Sci Rep 2022;12:14288. [PMID: 35995985 DOI: 10.1038/s41598-022-18251-3] [Reference Citation Analysis]
3 Vito A, Rathmann S, Mercanti N, El-Sayes N, Mossman K, Valliant J. Combined Radionuclide Therapy and Immunotherapy for Treatment of Triple Negative Breast Cancer. Int J Mol Sci 2021;22:4843. [PMID: 34063642 DOI: 10.3390/ijms22094843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Murphy JF. Frontiers in Cancer Immunotherapy. Cancer Immunology 2021. [DOI: 10.1007/978-3-030-50287-4_1] [Reference Citation Analysis]
5 Yang J, Tan Y, Cheke RA. Complexities and Bifurcations Induced by Drug Responses in a Pulsed Tumour-Immune Model. Int J Bifurcation Chaos 2020;30:2050104. [DOI: 10.1142/s0218127420501047] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yang J, Tan Y, Cheke RA. Thresholds for extinction and proliferation in a stochastic tumour-immune model with pulsed comprehensive therapy. Communications in Nonlinear Science and Numerical Simulation 2019;73:363-78. [DOI: 10.1016/j.cnsns.2019.02.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
7 Li Z, Wang K, Shi Y, Zhang X, Wen J. Incidence of second primary malignancy after breast cancer and related risk factors-Is breast-conserving surgery safe? A nested case-control study. Int J Cancer 2020;146:352-62. [PMID: 30861567 DOI: 10.1002/ijc.32259] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
8 Tsoutsou PG, Zaman K, Martin Lluesma S, Cagnon L, Kandalaft L, Vozenin MC. Emerging Opportunities of Radiotherapy Combined With Immunotherapy in the Era of Breast Cancer Heterogeneity. Front Oncol 2018;8:609. [PMID: 30619749 DOI: 10.3389/fonc.2018.00609] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
9 Wang K, Zhu GQ, Shi Y, Li ZY, Zhang X, Li HY. Long-Term Survival Differences Between T1-2 Invasive Lobular Breast Cancer and Corresponding Ductal Carcinoma After Breast-Conserving Surgery: A Propensity-Scored Matched Longitudinal Cohort Study. Clin Breast Cancer 2019;19:e101-15. [PMID: 30502219 DOI: 10.1016/j.clbc.2018.10.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
10 Poleszczuk J, Luddy K, Chen L, Lee JK, Harrison LB, Czerniecki BJ, Soliman H, Enderling H. Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res 2017;19:75. [PMID: 28666457 DOI: 10.1186/s13058-017-0870-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 9.2] [Reference Citation Analysis]
11 Kalina JL, Neilson DS, Comber AP, Rauw JM, Alexander AS, Vergidis J, Lum JJ. Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy. Cancers (Basel) 2017;9:E13. [PMID: 28134800 DOI: 10.3390/cancers9020013] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
12 Schölch S, Rauber C, Tietz A, Rahbari NN, Bork U, Schmidt T, Kahlert C, Haberkorn U, Tomai MA, Lipson KE, Carretero R, Weitz J, Koch M, Huber PE. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors. Oncotarget 2015;6:4663-76. [PMID: 25609199 DOI: 10.18632/oncotarget.3081] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 7.8] [Reference Citation Analysis]
13 Cacan E, Spring AM, Kumari A, Greer SF, Garnett-Benson C. Combination Treatment with Sublethal Ionizing Radiation and the Proteasome Inhibitor, Bortezomib, Enhances Death-Receptor Mediated Apoptosis and Anti-Tumor Immune Attack. Int J Mol Sci 2015;16:30405-21. [PMID: 26703577 DOI: 10.3390/ijms161226238] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
14 Safi S, Beckhove P, Warth A, Benner A, Roeder F, Rieken S, Debus J, Dienemann H, Hoffmann H, Huber PE. A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial). BMC Cancer 2015;15:988. [PMID: 26686362 DOI: 10.1186/s12885-015-2006-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
15 Elgström E, Eriksson SE, Ljungberg O, Bendahl PO, Ohlsson TG, Nilsson R, Tennvall J. Evaluation of immune cell markers in tumor tissue treated with radioimmunotherapy in an immunocompetent rat colon carcinoma model. EJNMMI Res 2015;5:47. [PMID: 26374556 DOI: 10.1186/s13550-015-0126-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
16 Hingorani M, Dixit S, Pugazhenthi P, Hawkyard S, Robertson A, Khafagy R. Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?-a report of three cases. Cancer Biol Med 2015;12:60-3. [PMID: 25859413 DOI: 10.7497/j.issn.2095-3941.2014.0025] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Elgström E, Eriksson SE, Ohlsson TG, Nilsson R, Tennvall J. Role of CD8-positive cells in radioimmunotherapy utilizing (177)Lu-mAbs in an immunocompetent rat colon carcinoma model. EJNMMI Res 2015;5:3. [PMID: 25853009 DOI: 10.1186/s13550-014-0079-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
18 Yang J, Tang S, Cheke RA. Modelling pulsed immunotherapy of tumour–immune interaction. Mathematics and Computers in Simulation 2015;109:92-112. [DOI: 10.1016/j.matcom.2014.09.001] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
19 Finkelstein SE, Salenius S, Mantz CA, Shore ND, Fernandez EB, Shulman J, Myslicki FA, Agassi AM, Rotterman Y, Devries T, Sims R. Combining Immunotherapy and Radiation for Prostate Cancer. Clinical Genitourinary Cancer 2015;13:1-9. [DOI: 10.1016/j.clgc.2014.09.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
20 Murphy JF. Frontiers in Cancer Immunotherapy. Cancer Immunology 2015. [DOI: 10.1007/978-3-662-44946-2_1] [Reference Citation Analysis]
21 Pinkawa M, Djukic V, Klotz J, Petz D, Piroth MD, Holy R, Eble MJ. Hematologic changes during prostate cancer radiation therapy are dependent on the treatment volume. Future Oncol 2014;10:835-43. [PMID: 24799064 DOI: 10.2217/fon.13.237] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
22 Burotto M, Singh N, Heery CR, Gulley JL, Madan RA. Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol 2014;4:351. [PMID: 25566495 DOI: 10.3389/fonc.2014.00351] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
23 Agassi AM, Myslicki FA, Shulman JM, Rotterman Y, Dosoretz DE, Fernandez E, Mantz CA, Finkelstein SE. The promise of combining radiation therapy and immunotherapy: morbidity and toxicity. Future Oncology 2014;10:2319-28. [DOI: 10.2217/fon.14.188] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
24 Konski A, Meyer JE, Joiner M, Hall MJ, Philip P, Shields A, McSpadden E, Choi M, Adaire B, Duncan G, Meropol NJ, Cescon TP, Cohen SJ. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. Radiother Oncol 2014;113:35-40. [PMID: 25441058 DOI: 10.1016/j.radonc.2014.08.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
25 Elvington M, Scheiber M, Yang X, Lyons K, Jacqmin D, Wadsworth C, Marshall D, Vanek K, Tomlinson S. Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Rep 2014;8:818-30. [PMID: 25066124 DOI: 10.1016/j.celrep.2014.06.051] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
26 Iyengar P, Gerber DE. Locally advanced lung cancer: an optimal setting for vaccines and other immunotherapies. Cancer J 2013;19:247-62. [PMID: 23708072 DOI: 10.1097/PPO.0b013e318292e51a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
27 Shore ND, Mantz CA, Dosoretz DE, Fernandez E, Myslicki FA, McCoy C, Finkelstein SE, Fishman MN. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Cancer Control 2013;20:7-16. [PMID: 23302902 DOI: 10.1177/107327481302000103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
28 Demaria S, Formenti SC. Radiotherapy effects on anti-tumor immunity: implications for cancer treatment. Front Oncol 2013;3:128. [PMID: 23734344 DOI: 10.3389/fonc.2013.00128] [Cited by in Crossref: 35] [Cited by in F6Publishing: 45] [Article Influence: 3.9] [Reference Citation Analysis]
29 Marsh JC, Goldfarb J, Shafman TD, Diaz AZ. Current Status of Immunotherapy and Gene Therapy for High-Grade Gliomas. Cancer Control 2013;20:43-8. [DOI: 10.1177/107327481302000107] [Cited by in Crossref: 19] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
30 Tomblyn MB, Katin MJ, Wallner PE. The New Golden Era for Radioimmunotherapy: Not Just for Lymphomas Anymore. Cancer Control 2013;20:60-71. [DOI: 10.1177/107327481302000109] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
31 Finkelstein SE. From Bench to Bedside: Bringing Immunotherapy into the Clinic. Cancer Control 2013;20:4-5. [DOI: 10.1177/107327481302000102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]